Key result
Malignant ovarian tumors linked to ~13% lower mean platelet volume versus benign lesions.
Why the study?
Preoperative diagnosis of ovarian cancer is challenging, leading to inappropriate surgical procedures, necessitating more reliable markers to distinguish benign from malignant ovarian lesions.
Does preoperative mean platelet volume distinguish between benign and malignant ovarian lesions?
Observational (n=79)
No
Does preoperative mean platelet volume distinguish between benign and malignant ovarian lesions?
The study aims to evaluate if mean platelet volume can serve as a preoperative marker to differentiate benign from malignant ovarian tumors.
Answers are grounded in this paper and cite their sources.
Preoperative MPV may aid differentiation of ovarian lesions; hypothesis-generating and requires prospective validation before any clinical use.
Even nowadays the diagnostic of ovarian cancer is difficult to be established preoperatively, and therefore a significant number of patients are submitted to a much too extensive or to an incomplete surgical procedure. Therefore attention was focused on identifying more reliable markers which might help the clinician to distinguish between benign and malignant ovarian lesions. The aim of the current paper is to analyze the differences between benign and malignant ovarian tumors based on the preoperative levels of the mean platelet volume.
No takes yet. Share an insight, caveat, or question.
Bacalbașa et al. (2023) conducted an observational in Ovarian tumors (n=79). Malignant ovarian tumors vs. Benign ovarian tumors was evaluated on Mean platelet volume (p=0.033). Patients with malignant ovarian tumors presented with significantly lower mean platelet volume compared to those with benign ovarian lesions (8.2 vs 9.45, p=0.033).
Synapse has enriched 10 related papers. Consider them for comparative context: